There are many valid reasons to push forward with legal reforms to advance psychedelic medicine. In the U.S., however, it is the treatment of PTSD that is bringing Republicans and Democrats together.
Articles
Cybin Inc. Reports Third Quarter Financial Results and Recent Business Highlights
Cybin announces its Q3 results, supported by a conference call. Cash as of Decemeber 31, 2021 of CAD$63.6 million.
Cybin Announces Grant of U.S. Patent Covering its Proprietary Compound CYB004 (Deuterated DMT) for the Treatment of Anxiety Disorders
Cybin announces receiving a composition of matter patent for its DMT-derived compound, CYB004 from the the USPTO.
Elemental Advisors Launches PSYK ETF Focused on the Medical Psychedelics Industry
A new U.S.-based psychedelics ETF will begin trading on the NYSE, symbol "PSYK".
Optimi Health Dealer’s License Granted by Health Canada
Optimi Health announces receiving its Dealer's License from Health Canada, allowing the possession, production and sale of psilocybin.
5 Superb Values In Psychedelic Stocks, 5 Different Reasons To Buy
Cheap stocks. Many reasons to invest. We selected five different companies who illustrated these value propositions.
Novamind Hosts Clinical Trial to Advance Ketamine Therapy for End-of-Life Patients
Novamind will host a Phase II clinical trial by the Ketamine Research Foundation for ketamine therapy for the terminally ill.
Amendments To Canada's Special Access Program (SAP) Allows Access To Restricted Psychedelic Drugs. How Will This Affect The Industry?
Mental health professionals have been exploring psychedelics as a treatment for substance abuse and mental health disorders for decades, and now its status as a legitimate treatment is being recognized in Canada.
Awakn Life Sciences Receives Bold Price Target From H.C. Wainwright
This morning, Awakn Life Sciences Corp. became the latest psychedelic company to obtain coverage under the H.C. Wainwright umbrella.
Has A Sugar Daddy Emerged In The Psychedelic Drug Industry?
As new deep pockets emerge to finance psychedelic drug development, we also learn that this R&D isn't as expensive as some drug companies claim.
Red Light Holland's Partner CCrest Laboratories Approved By Health Canada to Supply Psilocybin to the Special Access Program
Red Light Holland partner, CCrest Laboratories, has been approved by a Health Canada as a supplier of psilocybin for the SAP.
Novamind Announces Closing of CAD$5 Million Private Placement with Institutional Investor
Novamind announces the closing of its previously announced CAD$5 million private placement.
Psychedelic Medicine Blazing New Trails: A Q&A With CEO Anthony Tennyson and Dr. Celia Morgan
Beyond substance abuse, behavioral addictions are also a major problem in society. We went to addiction-specialist, Awakn Life Sciences to learn more these additional treatment markets.
atai Life Sciences Launches Invyxis to Accelerate Discovery of Next-Generation Mental Health Treatments
atai launches Invyxis, as a new company devoted to the creation of novel psychedelics molecules.
MINDCURE Announces Financial Results for the Second Quarter of Fiscal 2022
MINDCURE reports its Q2 fiscal 2022 results. The Company recorded a loss of CAD$2.95 million. Its cash position is now CAD$13.4 million.